Pharmascience announced the US Food and Drug Administration (FDA) communicated on October 31, 2019, the abbreviated new drug application (ANDA) for Pharmascience's generic version of Paliperidone Palmitate Extended-Release Injectable Suspension prefilled syringes, is accepted for review. Paliperidone Palmitate is indicated for the maintenance treatment of schizoaffective disorder.
"We at Pharmascience are extremely proud of this very important milestone," said Jack Gagnon, Vice President and General Manager, Pharmascience International, "This achievement is a testament to our capabilities in the development of complex injectable and solid oral formulations. Pharmascience is one of the few companies in North America that specialize in these complex formulations."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!